[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619322":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":34,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":7,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"University Hospital, Strasbourg, France","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Aurélien GUFFROY, MD","CONTACT","33 3 69 5512 23","aurelien.guffroy@chru-strasbourg.fr",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":19,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France","RECRUITING","Strasbourg","67091","France","FR",{"type":23,"coordinates":24},"Point",[25,26],7.74553,48.58392,{"lat":26,"lon":25},[29,30,32],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":31,"phone":7,"phoneExt":7,"email":7},"Jeannne MALLICK, MD",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100619322",false,"NCT07343115","Familial Systemic Scleroderma","SCLERO","Inclusion Criteria:\n\n* Adult subjects (≥ 18 years of age)\n* Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities\n* At least one first-degree relative with systemic scleroderma meeting the same criteria\n\nExclusion Criteria:\n\n\\- Subject who has expressed opposition to participating in the study","ALL","18 Years",{"count":45,"type":46},20,"ESTIMATED","OBSERVATIONAL","Studying familial forms of systemic scleroderma offers several advantages:\n\n1. To better understand the pathophysiology of a complex autoimmune disease based on \"extreme\" cases (familial forms);\n2. To identify potential molecular markers predictive of disease progression;\n3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.",[50],"Systemic Scleroderma",[50,39,52],"Autoimmune disease","2026-01-06",{"date":55,"type":56},"2026-01-15","ACTUAL",{"date":58,"type":56},"2025-09-02",{"date":60,"type":46},"2026-09-02",{"name":5,"class":6},1]